Molecular Partners (MOLN) and Orano Med said Tuesday that the latest preclinical data on their MP0712 product candidate confirmed "high tumor uptake" while keeping low kidney exposure.
The companies co-developed MP0712 as a radio-designed ankyrin repeat protein therapeutic candidate that targets delta-like ligand 3, according to the statement.
Molecular Partners and Orano Med said the latest data showed strong uptake by the targeted tissue, with minimal impact on health tissues. Dose-range finding studies in mice also confirmed that the treatment was well tolerated at relevant dosage.
The companies said they plan to start first-in-human studies in 2025, with initial clinical data on MP0712 expected within the same year.
Molecular Partners shares were up over 10% premarket.
Price: 7.47, Change: +0.69, Percent Change: +10.18
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。